NovoCure Limited (NASDAQ:NVCR) tinted loss of 0% (0 points) to US$33.35. The volume of 0.5 Million shares climbed down over an trading activity of 931.62 Million shares. EPS ratio determined by looking at last 12 month figures is -1.11. Over the same time span, the stock marked US$33.85 as its best level and the lowest price reached was US$16.1. The corporation has a market cap of US$2.96 Billion.
NovoCure Limited (NASDAQ:NVCR)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -56.7 percent while most common profitability ratio return on investment (ROI) was -41.4 percent. The company’s institutional ownership is monitored at 56.1 percent. The company’s net profit margin has achieved the current level of -33.1 percent and possesses 68 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.4. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Tower Semiconductor Ltd. (NASDAQ:TSEM) is worth US$2.15 Billion and has recently fallen 0% to US$21.83. The latest exchange of 0.46 Million shares is below its average trading activity of 787.83 Million shares. The day began at US$21.9 but the price moved to US$21.66 at one point during the trading and finally capitulating to a session high of US$21.97. The stock tapped a 52-week high of US$36.69 while the mean 12-month price target for the shares is US$38.17.
Currently, the stock carries a price to earnings ratio of 8.56, a price to book ratio of 2.01, and a price to sales ratio of 1.57. For the past 5 years, the company’s revenue has grown 16.8%, while the company’s earnings per share has grown 23.1%. With an institutional ownership near 8.2%, it carries an earnings per share ratio of 2.55.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.67.